Recent Updates
Recently added Catalysts
REGN

Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

Monday, March 3, 2014 1 min read
Key Takeaway: Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

Full Press Release Details

Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan.
Tags: REGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 3, 2014